logo oncology-news

Онкология  >  Новости онкологии

При финансовой поддержке logo MSD Oncology

Sarcomatoid RCC: dual checkpoint inhibition improves outcomes

Nivolumab plus ipilimumab improves survival irrespective of PD-L1 expression.